Amicus Therapeutics (NASDAQ: FOLD) reported Q2 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $80.7 million versus the consensus estimate of $85.87 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.